1) Hope Study 

The HOPE (Hepatoblastoma Origins & Pediatric Epidemiology) Study was designed to try to find causes of hepatoblastoma.

2.) Open (Recruiting) HB Related Clinical Trials –  

• Hepatoblastoma Biology Study and Tissue Bank

Intervention:  
Procedure: Biology Study and Tissue Banking  

• Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma

Intervention:  
Drug: irinotecan hydrochloride  

• Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma

Interventions:  
Drug: carboplatin;   
Drug: cisplatin;   
Drug: doxorubicin hydrochloride;   
Procedure: adjuvant therapy;  
Procedure: conventional surgery;   
Procedure: neoadjuvant therapy  

• Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, or Osteosarcoma

Interventions:  
Drug: sodium thiosulfate;   
Procedure: observation  

• Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer

Interventions:  
Drug: cisplatin;   
Drug: sodium thiosulfate;   
Procedure: adjuvant therapy;   
Procedure: gene expression profiling;   
Procedure: gene rearrangement analysis;   
Procedure: immunohistochemistry staining method;   
Procedure: laboratory biomarker analysis;   
Procedure: neoadjuvant therapy;   
Procedure: proteomic profiling;   
Procedure: therapeutic conventional surgery  

• Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

Conditions:  Ewing's Sarcoma;   Soft Tissue Sarcoma;   Hepatoblastoma;   Hodgkin's Disease; Germ Cell Tumor Intervention:  
Drug: High-Dose Chemotherapy with Tandem PBSC Rescue.  

• Bone Marrow Radiation Therapy Followed by Busulfan, Melphalan, Thiotepa, and an Autologous Stem Cell Transplant in Treating Patients With High-Risk or Relapsed Solid Tumors

Conditions:  Brain and Central Nervous System Tumors,   Kidney Cancer, Liver Cancer,   Retinoblastoma,   Sarcoma,   Unspecified Adult Solid Tumor- Protocol Specific,   Unspecified Childhood Solid Tumor- Protocol Specific
Interventions:  
Drug: busulfan;   
Drug: etoposide;   
Drug: filgrastim;   
Drug: ifosfamide;   
Drug: melphalan;   
Drug: sargramostim;   
Drug: thiotepa;   
Procedure: autologous bone marrow transplantation;   
Procedure: autologous hematopoietic stem cell transplantation;   
Procedure: intensity-modulated radiation therapy;   
Procedure: peripheral blood stem cell transplantation;   
Procedure: pharmacological study;   
Procedure: positron emission tomography;   
Procedure: tomotherapy;   
Procedure: total marrow irradiation
 

3) Hepatoblastoma Biology Study and Tissue Bank –


Although tremendous improvement in the treatment of childhood cancer has resulted from the use of clinical trials, it is clear that additional significant progress will require a better understanding of the molecular makeup of pediatric malignancies. Hepatoblastoma, an embryonal tumor of the liver, is rare in the general population. It occurs in approximately 1 in 50,000 children. However, families affected with Familial Adenomatous Polyposis, in which there is a high incidence of colon cancer, have an 850 fold increase in the frequency of Hepatoblastoma. Hepatoblastoma also occurs in association with Beckwith-Wiedemann Syndrome.  Thus the occurrence of Hepatoblastoma suggests the need for both careful investigations into the family history of malignancies in relatives, as well as a search for genetic alterations that may contribute to tumor development. COG cancer researchers are trying to better understand the causes of Hepatoblastoma. They want to develop improved methods for treatment, diagnosis and possibly even prevention. The exact molecules or genes to be studied will change over time as progress in cancer research is made. Not every gene or molecule known to be involved in cancer will be studied. Researchers will choose to study only those genes or molecules which they think are most promising. At present, the study of at least three genes is planned. In some cases these changes may be detected in normal tissues such as liver or blood cells. One of the genes to be studied is known as the APC gene.  It is linked with colon cancer in adults. Rarely this gene can be passed on in families which are prone to develop both colon cancer and Hepatoblastoma. We don't know how common changes in this gene are in children with Hepatoblastoma. This study will try and figure out if this gene is commonly changed in Hepatoblastoma. In addition to studying specific genes or molecules, geneticists (doctors who specialize in looking at genes) will look at the overall genetic content of tumors from some of the children involved in this study. This will be done by what is known as a karyotype or chromosome analysis. It is known that  some Hepatoblasomas have extra copies of certain chromosomes. However, we do not know what effect these extra chromosomes might have on predicting which children will be most likely to respond to treatment. One of the goals of the study is to figure out what biological factors within the tumors, including extra chromosomes, might help predict which children will respond best to treatment. This will hopefully lead to better treatment of Hepatoblastoma.